HLB Conducts 0.05 Shares Bonus Issue Per Share "As Part of Shareholder Returns"

"Shareholder Returns Following Main Review Entry for Liver Cancer New Drug Approval"

HLB announced on the 19th that it will conduct a stock dividend issue amounting to approximately 6.13 million shares.

HLB logo. [Image provided by HLB]

The record date for this stock dividend is August 3rd, with an allocation of 0.05 shares of common stock and 0.05 shares of other stock per one share held. Accordingly, shareholders holding shares by the record date will receive 5 shares for every 100 shares held as a stock dividend. The new shares will be listed on August 21st. The source of the stock dividend is capital surplus, which reached 1500% as of the first quarter.

HLB explained that this stock dividend is in the nature of a stock distribution. HLB stated that the stock dividend is being conducted as a token of appreciation for the long-standing support of shareholders following the U.S. Food and Drug Administration (FDA)'s approval of the new drug application review for the combination therapy of Rivoceranib and Camrelizumab. HLB had previously declared shareholder-friendly policies such as stock dividends in response to shareholder requests at the shareholder meeting held in the second half of last year.

Han Young-in, HLB's Chief Financial Officer (CFO), said, "At this moment when we are the first domestic company to be on the verge of new drug approval for a first-line treatment for liver cancer, we decided on this stock dividend as a way to express our deep gratitude to our shareholders," adding, "We will continue to expand shareholder-friendly policies going forward."

This content was produced with the assistance of AI translation services.